Daniel Stetson
Overview
Explore the profile of Daniel Stetson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1833
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shaw J, Page K, Wren E, de Bruin E, Kalashnikova E, Hastings R, et al.
JCO Precis Oncol
. 2024 May;
8:e2300456.
PMID: 38691816
Purpose: Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. Methods:...
2.
Fitzsimons L, Tasouri E, Willaredt M, Stetson D, Gojak C, Kirsch J, et al.
Dev Dyn
. 2023 Sep;
253(3):312-332.
PMID: 37776236
Introduction: Primary cilia play pivotal roles in the patterning and morphogenesis of a wide variety of organs during mammalian development. Here we examined murine foregut septation in the cobblestone mutant,...
3.
Roschewski M, Patel M, Reagan P, Saba N, Collins G, Arkenau H, et al.
Clin Cancer Res
. 2023 Jun;
29(17):3301-3312.
PMID: 37364001
Purpose: Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit widespread use. The selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib has...
4.
Abbosh C, Frankell A, Harrison T, Kisistok J, Garnett A, Johnson L, et al.
Nature
. 2023 Apr;
616(7957):553-562.
PMID: 37055640
Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells persisting after curative intent therapy. The study of large patient cohorts incorporating longitudinal plasma sampling and...
5.
Hernandez K, Bramlett K, Agius P, Baden J, Cao R, Clement O, et al.
J Mol Diagn
. 2023 Feb;
25(3):143-155.
PMID: 36828596
The Blood Profiling Atlas in Cancer (BLOODPAC) Consortium is a collaborative effort involving stakeholders from the public, industry, academia, and regulatory agencies focused on developing shared best practices on liquid...
6.
Zhang Y, Blomquist T, Kusko R, Stetson D, Zhang Z, Yin L, et al.
Genome Biol
. 2022 Jun;
23(1):141.
PMID: 35768876
Background: Clinical laboratories routinely use formalin-fixed paraffin-embedded (FFPE) tissue or cell block cytology samples in oncology panel sequencing to identify mutations that can predict patient response to targeted therapy. To...
7.
Lipsyc-Sharf M, de Bruin E, Santos K, McEwen R, Stetson D, Patel A, et al.
J Clin Oncol
. 2022 Jun;
40(22):2408-2419.
PMID: 35658506
Purpose: To examine the prevalence and dynamics of circulating tumor DNA (ctDNA) and its association with metastatic recurrence in patients with high-risk early-stage hormone receptor-positive breast cancer (HR+ BC) more...
8.
Stetson D, Ahmed A, Xu X, Nuttall B, Lubinski T, Johnson J, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-9.
PMID: 35100678
Purpose: Discordance between plasma and tumor variant calling has been attributed primarily to tumor heterogeneity, whereas technical variables remain largely unexplored. Materials And Methods: To measure these variables, we tested...
9.
Williams P, Forbes T, Lund S, Cole K, He H, Karlovich C, et al.
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34250423
Methods: In this phase I study, QCMs with 14 clinically relevant mutations representing single nucleotide variants, insertions or deletions (indels), translocations, and copy number variants were sourced from three commercial...
10.
Gong B, Li D, Kusko R, Novoradovskaya N, Zhang Y, Wang S, et al.
Genome Biol
. 2021 Apr;
22(1):109.
PMID: 33863344
Background: Targeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing reference materials characterized by the U.S. Food and Drug Administration-led SEquence...